



## PROGRAM TOPICS

### CERVICAL CANCER SCREENING

How effective is HPV genotyping in screening?

**J. Bonde (Denmark)  
& J. Dillner (Sweden)**

Cervical cancer screening: Harms and benefit ratio  
in the changing world of cervical cancer screening

**M. Rebolj (UK)  
& S. Van Dijk (Netherlands)**

Screening for HPV-vaccinated cohorts:  
Country-specific experience

**J. Lei (Sweden)  
& P. Sasieni (UK)**

The utility of urine for improved cervical cancer prevention

**A. Vorsters (Belgium)**

Risk stratification in cervical cancer screening

**H. Berkhof (Netherlands)  
& F. Inturrisi (Netherlands)**

Self-sampling

**G. Ogilvie (Canada)  
& M. Saville (Australia)**

Self-sampling implementation

**J. Bonde (Denmark)  
& M. Poljak (Slovenia)**

What role of cytology in HPV screening:  
Are we really ready to abandon morphological data  
completely and use only virological data?

**F. Carozzi (Italy)**

## VACCINATION

Gender-neutral vaccination: Impact on speed of elimination and subsequent need for screening

**E. Franco (Canada)**

**& M. Lehtinen (Finland)**

One-dose vaccination: What do we know, what will we know and what are the remaining evidence gaps?

**M. Brisson (Canada)**

**& M. Jit (UK)**

Vaccination hesitancy, recovery and public advocacy

**S. Hanley (UK)**

**& I. Olkov (France)**

PERCH(PartnERship to Contrast HPV):  
an EU Joint Action aiming for improved HPV vaccination coverage and data collection

**M. Arbyn (Belgium)**

**& R. Bucciardini (Italy)**

Scientific approaches to definition of HPV vaccine-induced protective immunity

**S. Beddows (UK)**

**J. Dillner (Sweden)**

**& M. Lehtinen (Finland)**

Multi-sector partnerships to accelerate HPV vaccination:  
Real world evidence

**M. Fisher-Borne (USA)**

## CLINICAL SESSIONS

Use of genotyping for management

**F. Carozzi (Italy)**

**& F. Inturrisi (Netherlands)**

Persistent HPV without HSIL lesions in colposcopy

**K. Louvanto (Finland)**

Vaccination in women with CIN treatment

**P. Nieminen (Finland)**

**& B. Strandér (Sweden)**

Colposcopy

**G. Donders (Belgium)**

HPV genital diseases during pregnancy

**K. Louvanto (Finland)**

**& E. Siegler (Israel)**

## ANAL CANCER

Putting anal cancer screening into practice:

Implementation science, biomarker development,  
and self-sampling

**A. Burchell (Canada)**

**& A. Nyitray (USA)**

Implementation of anal cancer screening:

Challenges and solutions

**J. Palefsky (USA)**

## HIGH-RISK POPULATIONS

Research to advance prevention of cervical and HPV-related cancers among women living with HIV

**A. Giuliano (USA)**

**& V. Sahasrabuddhe (USA)**

Sexual abuse and HPV

**A. B. Moscicki (USA)**

HPV driven cancer among people living with HIV

**A. B. Moscicki (USA)**

**& M. Muchengeti (South Africa)**

Cervical cancer screening in LMICs

**J. Smith (USA)**

Screening for HPV-related cancer in sexual and gender minority adults

**S. Jackson (USA)**

**& A. Kreimer (USA)**

HPV vaccination in vulnerable populations

**M. Bardou (France)**

**& I. Baussano (France)**

## OTHER SESSIONS

Validation of HPV assays	<b>M. Arbyn (Belgium)</b> <b>&amp; K. Cuschieri (UK)</b>
Global overview of commercial HPV tests: 2024 status	<b>K. Cuschieri (UK)</b> <b>&amp; M. Poljak (Slovenia)</b>
Methylation markers as management tool in anal, vulvar and cervical intraepithelial neoplasms	<b>M. Bleeker (Netherlands)</b> <b>&amp; M. Clarke (USA)</b>
Indications for methylation testing in cervical screening and in the diagnosis of cervical and non-cervical HPV-associated lesions	<b>D. Heideman (Netherlands)</b> <b>&amp; R. Steenbergen (Netherlands)</b>
Newest insights into oncogenesis	<b>J. Doorbar (UK)</b> <b>&amp; R. Steenbergen (Netherlands)</b>
Present status of genome-wide association studies	<b>P. Hillemanns (Germany)</b>
Microbiome	<b>C. Bouchard (Canada)</b> <b>&amp; G. Ogilvie (Canada)</b>
Newest insights into HPV epidemiology	<b>S. Franceschi (Italy)</b> <b>&amp; A. Kreimer (USA)</b>
Challenges and implications of viral load and cellularity measurements	<b>M. Arbyn (Belgium)</b> <b>&amp; C. Cocuzza (Italy)</b>
Global HPV laboratory network	<b>S. Arroyo Mühr (Sweden)</b> <b>&amp; K. Cuschieri (UK)</b>

## SPECIALIZED WORKSHOPS

Vulvar diseases	<b>M. Bleeker (Netherlands)</b> <b>&amp; M. Hampl (Germany)</b>
Colposcopy course	<b>J. Bornstein (Israel)</b> <b>&amp; A. Singer (UK)</b>

## NORDIC COUNTRIES WORKSHOP

Coordinators: J. Bonde (Denmark) – J. Dillner (Sweden)

### The Nordic Session - Part 1

Next level for HPV vaccine in the nordic countries

**J. Bonde (Denmark)  
& J. Dillner (Sweden)**

### The Nordic Session - Part 2

Next level for cervical screening in the nordic countries

## HPV AND HEAD & NECK FORUM

Coordinators: C. Brenner (USA) – J. P. Klussmann (Germany)  
K. Lang Kuhs (USA) – S. Virani (France)

Epidemiology and prevention of HPV-OPC

**E. Rettig (USA)**

Screening for HPV-OPC

**K. Lang Kuhs (USA)  
& T. Waterboer (Germany)**

Basic science

**C. Brenner (USA)  
& S. Virani (France)**

Management

**H. Mirghani (France)**

Molecular diagnosis and surveillance

**J. P. Klussmann (Germany)**

Recurrent respiratory papillomatosis (RRP)

**S. Best (USA)**